Work

Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2622

Authors: Karim Rihawi, Michael Ong, Vasiliki Michalarea, Liz Bent, Susanne Buschke, Thomas Bogenrieder, Alan Anthoney, Johann Sebastian De Bono, Chris Twelves

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Ottawa, Royal Marsden Hospital, Boehringer Ingelheim (United Kingdom), Boehringer Ingelheim (Germany), Boehringer Ingelheim (Austria), Cancer Research UK, University of Leeds, St James's University Hospital

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3147269955

Cites:

Cited by: 5

Related to: 10